Health AI Central
Peer-Reviewed Publication
Ann Diagn Pathol2026;85152711.December 1, 2026Journal Article

When morphology suggests a fusion: A pathology-centered escalation framework from histology and immunohistochemistry to RNA sequencing.

Miaomiao Jiang1, Lupeng Ji2, Hui Zhang3, Chao Yuan4
1The Second Affiliated Hospital of Jiaxing University, Jiaxing, China. Electronic address: shuilaimingyu@126.com.
2The Second Affiliated Hospital of Jiaxing University, Jiaxing, China. Electronic address: 15967339519@163.com.
3Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Shenzhen, China. Electronic address: zhanghui_i@mindray.com.
4Hangzhou Adicon Clinical Laboratories Co., Ltd., West Lake District, Hangzhou, China. Electronic address: 13456299385@163.com.
PubMed DOI

Abstract

Gene fusions have moved from ancillary molecular findings to defining events for an expanding group of neoplasms, with consequences for tumor classification, diagnostic certainty, and, in selected settings, targeted therapy. Yet the practical problem facing pathologists is not simply whether fusion testing is available, but when morphology should trigger it, which assay should be selected, and whe…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.